Close menu




November 9th, 2022 | 13:31 CET

BioNTech, Porsche and Pathfinder Ventures - Looking good

  • Camping
  • RV
  • Biotechnology
Photo credits: pixabay.com

BioNTech's figures were convincing, and the chart looks good again. Porsche is doing well. Not all analysts see further price potential and the price targets diverge. However, a promotion to the DAX beckons. Pathfinder Ventures is also benefiting from surprisingly high demand. The winter camping resort offers are practically sold out. But first to BioNTech. After competitor Moderna had disappointed last week, the quarterly figures of the Mainz-based biotech Company were convincing. And due to the full pipeline, investors can expect a lively news flow in the coming year. Analysts are bullish.

time to read: 3 minutes | Author: Fabian Lorenz
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , PORSCHE AG | DE000PAG9113 , PATHFINDER VENTURES INC | CA70323P1071

Table of contents:


    Joe Bleackley, CEO, Pathfinder Ventures Inc.
    "[...] In addition to campsite fees, Pathfinder Ventures has put itself in a position to offer all of these sought-after camping solutions. The only thing they don't sell is the RV itself. [...]" Joe Bleackley, CEO, Pathfinder Ventures Inc.

    Full interview

     

    BioNTech: More than EUR 15 billion in the cash box

    Berenberg continues to recommend BioNTech's stock as a "buy" after the publication of the quarterly figures. The price target remains unchanged at USD 312. Thus, the analysts see almost 100% price potential. They were pleased with the continued high revenues from the sale of the COVID-19 vaccine. These are resilient, they said. Now the focus is on the coming year and the development pipeline. With that, some positive momentum can be expected. Review: BioNTech had sales of about EUR 3.5 billion in the third quarter. Net income was a tidy EUR 1.8 billion, which is more than analysts had expected on average.

    In addition, the Mainz-based biotech Company specified its forecast for the full year 2022 at the upper end. Thus, annual sales are expected to be EUR 16 to 17 billion (previously EUR 13 to 17 billion). At the end of the third quarter, BioNTech already had a bulging treasury. The Company had EUR 13.4 billion in cash and cash equivalents at its disposal. In addition, a large part of the EUR 7.3 billion in trade receivables outstanding at the reporting date had already been received. As a result, the Company is fully financed for the coming years. To put this in perspective: In the current year, the costs for research, sales/administration and capital expenditures will total a maximum of EUR 2.6 billion. That means the Company can continue to go full throttle, particularly in cancer research. The pipeline currently comprises 19 product candidates in 24 ongoing clinical trials. For the coming year, BioNTech expects new data from up to 10 clinical trials.

    Pathfinder Ventures: Cash register rings even in winter

    Pathfinder Ventures is still a long way from billions in sales. Nevertheless, the Canadians have an exciting growth story. The Company is currently building a network of upscale, family-friendly campgrounds and RV parks in western Canada. In this way, it benefits from the trend toward self-directed vacations in the great outdoors. Pathfinder is only at the beginning of its growth and investment phase. Still, the operating result is already profitable at this early stage - especially important in an environment of rising interest rates. There is plenty of growth potential for the coming years. The camping market in Canada alone is worth CAD 2.3 billion - and expansion into the US should not be a major problem.

    Contrary to what may be assumed, the Company also generates revenue in the winter months, with the winter vacation program running since mid-October. Guests stay at Pathfinder Camp Resorts until mid-April. And the offer is in high demand. The booking rate is currently 47%, the Company said. 96% of the locations in the winter vacation program are already fully booked to date. Therefore, capacities are to be increased in the coming winter. "We are extremely pleased with these numbers as we strive for continued growth in all of our resorts for what has been called the 'off-season,'" said Joe Bleackley, Pathfinder's CEO. Pathfinder is thus demonstrating that it is not only growing through acquisitions but also continuing to develop its existing locations.

    Porsche: Price targets diverge significantly

    It has now been 30 days since Porsche's IPO. That means the standstill period for the accompanying banks has ended, and their analysts can now have their say. As a result, there were six new research studies on the sports car pioneer yesterday. Four analysts recommend buying, and two recommend holding. JPMorgan is the most optimistic. The analysts name a target price of EUR 140. The earnings momentum is easy to plan for, even in otherwise uncertain times. And thanks to its pricing power, the challenges surrounding inflation, electrification and autonomous driving are easy to master. As a result, Porsche is a highly attractive opportunity to be part of the luxury car segment. Morgan Stanley is more pessimistic. Porsche is a mixture of carmaker and luxury group, they said. But the impending recession would also put Porsche's business model to the test. Therefore, the analysts give the stock an "Equal Weight" with a price target of EUR 82.50. The sports car manufacturer's share is currently trading at around EUR 100. New price momentum could come with the possible promotion to the DAX.


    BioNTech is still on track: the cash box is bulging to drive the development pipeline forward. While the COVID-19 vaccine is yielding less profit, the business is far from dead. Pathfinder Ventures is an interesting exotic. Management shows that they are not only growing through acquisitions but also by developing existing sites. At Porsche, there is a current lack of impetus for further share price increases.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by André Will-Laudien on February 20th, 2024 | 07:30 CET

    Takeover fever in the biotech sector! Will MorphoSys now be followed by Defence Therapeutics, Evotec and Bayer?

    • Biotechnology
    • Pharma
    • Innovations

    It has happened: Novartis is bidding for MorphoSys. Once again, a long-lasting and persistent rumour mill eventually confirms itself. Those who remained loyal to MorphoSys despite heavy selling last fall have now made a profit of over 300%. If we turn the analytical magnifying glass on the sector, we can see that the speculative biotech stock market segment has started to move again since the challenging year 2023. Hopes of falling interest rates in the near future, along with several other M&A hopes, have led to steady inflows into listed bio-ETFs, resulting in fund managers having recently adjusted their weightings upwards. We analyze which stocks are currently making the loudest noise.

    Read

    Commented by André Will-Laudien on February 16th, 2024 | 07:00 CET

    MorphoSys and Cardiol Therapeutics in upward mode, while Bayer and Pfizer are in slow mode

    • Biotechnology
    • Pharma

    The biotech sector has made a very differentiated start to the new year. While the old favorites are barely moving, the second-line stocks MorphoSys and Cardiol Therapeutics are making a real splash. At Bayer, the bad news just won't go away, and despite a successful major takeover, Pfizer has not yet found its forward gear. After a rally of almost 15% in December, the Nasdaq Biotechnology Index (NBI) has taken a pause in the current year. Now, everyone is waiting for the first interest rate cut by central banks. Inflation is already falling, and the negative economic data for the Eurozone is increasing. The ECB would normally be in demand. What should investors urgently keep an eye on?

    Read

    Commented by Armin Schulz on February 12th, 2024 | 07:00 CET

    MorphoSys, Defence Therapeutics, Bayer - Biotech and Pharma suddenly back in focus

    • Biotechnology
    • Pharma

    Biotech ETFs have been on the rise since the end of October 2023. German biotech companies were able to raise more funds again last year. There are increasing signs that the tough times for investors in biotech and pharmaceutical companies are over. There is also growing activity on the takeover side. Most recently, the takeover bid from Novartis shifted the focus to companies in the healthcare sector. The Swiss pharmaceutical company wants to acquire MorphoSys for EUR 2.7 billion and thus fill up its oncology pipeline. We have selected three companies from the biotech and pharma sectors and examined their current situation.

    Read